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    Fer 18 cases of carcinoma of the prostat’6 pathohistologically proved at the Hiroshima University
’Hospital， castration was performed followed by estrogen therapy er by radiotherapy． Plasma testosterone・
and testosterone－estradiol bincling glubulin（TeBG）levels were measured in terms of each treatment．
Effects of anti－androgenic agents on the binding of TeBG with testosterone ’翌?窒?investigated in in
vitro system． The following results were obtained．
    1）Castration brough．ヒare血arkable．rcduction of’ plas皿a le＞els of testosterone and a rise of TeBG
to 120％of tlle pre－castration lcveL A章er♀04ays斧dminlstr斧tion of DES－diphosphate 500 mg per day，
some cases showed striking reduction of testosterone level plasma to the non－measurable level， whereas
TeBG rose to appxoximately 2．5 ti皿es of pre－treatment Ievel．
    In the group receiving radiotherapy， plasma testosterone remained at the level of post－castrati6n
whereas TeBG also remairied at an increased 1280／， of pre－treatment level， which was almost the
same as post－castration level．
    2） ln vitro study demonstrqted an effect of cyproterone acetate on binding of ’1’eBG with testo－
sterone， but no effect ef DES－diphosphate， stilbesterol or spironolactone．
    Therefore， striking rise of TeBG in prostatic cancer patients on DES－diphosphate administration
capnot be gxplained by binding of TeBG with stilbestrol， an active form of DES－diphosphate．’ Pro－
moted productien of TeBG・by liver cells is suggested． lts increased part might bind with unbound






























































































































   pre  l／2  1     2      3      4wk
    量reqf．        After the ＄tart of treatment
Fig． 1． Weekly changes of testosterone and TeBG
    levels in patients with prostatic carcinoma


















pie V2 1 4 8 wk
treat．    After the start of treatment
Fig． 2． Weekly changes of testosterone and TeBG
    levels in patients with prostatic carcinoma
    （castration十irradiation）
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Fig．4． Infiuence of estradiol on binding of 3H－testos亡erone to TcBG．


















Fig．5． Influence of cypro亡erone acetate oll binding of 3H一亡estGsterone亡。 TeBG．
 3） CAの影響（Fig・5）
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